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The scientific basis for offering seasonal influenza immunisation
to risk groups in Europe
Abstract
This paper summarises the scientific evidence supporting selection of risk groups that would benefit
from annual seasonal influenza immunisation in European Union (EU) countries. Risk groups are
defined restrictively as persons in Europe at higher than average risk of adverse outcomes should they
be infected with seasonal influenza and for whom use of vaccine is demonstrated to be effective in
reducing the risk of those outcomes. Existing evidence indicate that older people and those with chronic
disease are at higher risk of severe adverse outcome and that immunisation reduces this risk. There is
thus good scientific evidence for routinely offering annual immunisation to all older people (at least
those aged 65 years and older), and people with certain groups of chronic medical conditions. We
estimated that these two groups account for between 19% and 28% of the population of EU countries.
Thus in 2006, an estimated 84 million older people aged 65 years and over and 41 million people
younger than 65 years of age with chronic conditions were living in these countries. There is also strong
evidence for immunising staff caring for patients belonging to these two risk groups in residential (care
home) settings in order to protect the patients. There are as yet no strong data on whether or not
immunising other healthcare workers and carers protect patients though immunisation of healthcare
workers can be justified on occupational health grounds. At present the scientific evidence for
immunising other suggested risk groups, notably children and pregnant women is not strong for Europe
though equally there is no evidence against immunising these groups.
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This paper summarises the scientific evidence supporting selection 
of risk groups that would benefit from annual seasonal influenza 
immunisation in European Union (EU) countries. Risk groups are 
defined restrictively as persons in Europe at higher than average risk 
of adverse outcomes should they be infected with seasonal influenza 
and for whom use of vaccine is demonstrated to be effective in 
reducing the risk of those outcomes. Existing evidence indicate 
that older people and those with chronic disease are at higher risk 
of severe adverse outcome and that immunisation reduces this 
risk. There is thus good scientific evidence for routinely offering 
annual immunisation to all older people (at least those aged 
65 years and older), and people with certain groups of chronic 
medical conditions. We estimated that these two groups account 
for between 19% and 28% of the population of EU countries. 
Thus in 2006, an estimated 84 million older people aged 65 years 
and over and 41 million people younger than 65 years of age with 
chronic conditions were living in these countries. There is also 
strong evidence for immunising staff caring for patients belonging 
to these two risk groups in residential (care home) settings in order 
to protect the patients. There are as yet no strong data on whether 
or not immunising other healthcare workers and carers protect 
patients though immunisation of healthcare workers can be justified 
on occupational health grounds. At present the scientific evidence 
for immunising other suggested risk groups, notably children and 
pregnant women is not strong for Europe though equally there is 
no evidence against immunising these groups. 
*OUSPEVDUJPO
Most people are susceptible to influenza infection and there are 
various estimates of the numbers that are infected each year, the 
resulting burden of ill-health and to what extent this burden can 
be reduced. All of these conclude that human seasonal influenza 
is a serious public health threat which occurs annually but can be 
significantly ameliorated [1,2]. Influenza vaccines are the most 
effective preventive tools available for reducing that burden and the 
risk to individuals [3-5]. The immunisation strategy for preventing 
human seasonal influenza aims at protecting vulnerable individuals, 
rather than trying to achieve herd immunity and reduce transmission 
in the community [6]. Some individuals and groups are more likely 
to develop severe disease and even die as a result of their infection 
[2,7-12]. Hence, since the first influenza vaccines were developed 
the strategy has been to immunise certain so-called ‘risk groups’ 
rather than whole populations [13].
Another reason for this selective strategy is the frequent change 
in circulating viruses and subsequently the need to regularly review 
the composition of influenza vaccines and to conduct immunisation 
annually. This introduces an unusually high level of expense and 
logistical considerations into vaccine production and delivery [14]. 
In addition to the traditional ‘risk groups’ (older people and people 
with chronic illnesses [6]) influenza vaccination is sometimes 
recommended to other groups and individuals who may or may not 
be at any higher than average risk of severe disease should they be 
infected. According to the VENICE study these groups in different 
EU countries include: pregnant women, children (under age of two 
or five years), persons living with those at higher risk, healthcare 
and other care workers, those working in essential, military and 
veterinary services, and poultry workers [15].
In 2003 the World Health Assembly (WHA) in a resolution 
concerning pandemic and seasonal influenza urged all its member 
states “to establish and implement strategies to increase vaccination 
coverage of all people at high risk, including the elderly and persons 
with underlying diseases” [16]. The resolution neither specified the 
age of the elderly nor any list of these underlying diseases and the 
scientific and public health background for the recommendation 
from the Assembly’s secretariat in the World Health Organization 
(WHO) is unrecorded. Some subsequent specification can be found 
on the WHO web, where the high risk groups are described as: the 
elderly, people with weakened immune systems and those with 
underlying chronic diseases where influenza often leads to severe 
pneumonia and other serious illness due to pre-existing chronic 
diseases [17]. The WHA also recommended a coverage target for 
immunisation of the elderly of 50% by the year 2006 and 75% by 
the year 2010 [16]. No target for those with chronic illness was 
specified. All European Union (EU) countries are members of the 
WHA and none expressed a reservation to the resolution.  
This paper is one of a series of outputs by the European Centre 
for Disease Prevention and Control (ECDC) providing scientifically-
based public health information and advice concerning seasonal 
influenza vaccination in Europe, and its main aim is to summarise 
the scientific evidence supporting selection of risk groups. It also 
seeks to estimate the number of people in the two main identified 
risk groups and the proportion they constitute of the population in 
the EU countries and in EU as a whole.
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The term risk groups has been used in various ways in literature, 
e.g. persons at higher risk than average for acquiring influenza, 
persons at higher than average risk of transmitting influenza, 
persons at higher risk of having an adverse outcome (severe disease 
or death) should they acquire infection or persons who if they 
acquire influenza are more likely to transmit the infection to others 
who will then develop severe disease.
In this paper we employ a restrictive definition, namely “persons 
in Europe at higher than average risk of adverse outcomes should 
they be infected with seasonal influenza and for whom use of 
seasonal influenza vaccination is demonstrated to be effective in 
reducing the risk of those outcomes”. 
We did a review of published scientific literature in the field. The 
literature search firstly focused on articles mentioning risk factors 
for experiencing severe outcomes following influenza infection. 
Secondly publications were sought that investigated whether 
influenza immunisation reduced risks of severe outcome or that 
it was at least protective against any influenza infection. It was 
also investigated whether the literature supported the view that 
immunisation of others, notably healthcare staff and other carers, 
protected people in the risk groups. 
The strategy was to search the PubMed database without date 
restriction up to September 2008, for relevant articles in English, 
using medical subject headings (MESH) identifying the disease 
(Human Influenza, Flu), the clinical outcome (hospitalisation/
hospital*, mortality, death, pneumonia, morbidity) and a list of 
pre-identified possible broad risk factors (cardiovascular, chronic 
respiratory/COPD, diabetes, immunosuppression/immunodeficiency, 
HIV, transplant, pregnancy/pregn*, renal failure/dialysis/
haemodialysis, elderly/old, child*/infant). To select the subset of 
studies also reporting “vaccine effectiveness” estimates we included 
this term in each search considering only articles where vaccine 
effectiveness was mentioned in the title or abstract. We screened 
the retrieved articles by reading their abstracts and selected those 
that were most relevant in terms of article type (reviews, guidelines, 
large cohorts, meta-analyses) and appropriateness of the content. 
The literature was screened to select studies based on European 
populations, and where possible we gave more emphasis to European 
studies on increased risk of severe clinical outcome in the various 
risk groups studies as there may be European specific features in 
terms of prevalence of risk factors and burden of disease that make 
the results of non-European studies difficult to generalise. This is 
less the case for vaccine effectiveness studies.
Articles included in the references of reviews, guidelines and 
meta-analyses were added where they had not been retrieved by 
the PubMed search. In addition, we drew on a review undertaken 
for an ECDC-convened scientific panel on immunisation of children 
in 2006-7 [18] and a systematic review commissioned by ECDC 
on methods for measuring influenza vaccine effectiveness and 
undertaken by the organisation Epiconcept (http:www.epiconcept.
fr) [19]. 
The planning estimates of the size of population in the risk 
groups were made for the elderly and for those with chronic 
conditions in younger years. For the population aged 65 years and 
older we used published European population statistics for the year 
2004 and with projections made forward to 2050 [20]. Estimating 
the number of people with chronic conditions in the influenza risk 
groups was more difficult, as estimates of chronic ill-health are 
usually not available in the routine statistics and what exists does 
not conform to the risk groups for influenza which do not comprise 
all persons with chronic medical and physical conditions. 
A specific issue to address was to avoid double counting of 
persons both aged 65 years and older and with chronic conditions. 
A large cohort study in Sweden showed that the prevalence of 
multiple morbidity among older individuals reaches 55% [21]. To 
overcome this, we excluded European studies where the distribution 
of chronic conditions was not stratified by age or where double 
counting due to co-morbidity was not eliminated [22,23], which 
in some studies resulted in implausible differences between 
neighbouring countries [24]. Data available from the Global Burden 
of Disease and Risk Factors (GBD) project which overcomes double 
counting could not be used either because it does not directly 
describe the distribution of risk factors relevant to influenza in the 
general population [25]. 
The only survey identified that avoided double counting and 
selected the risk factors for influenza was the one undertaken in 
the United Kingdom, which used primary care data specifically 
for planning the needs for influenza vaccine [26]. This study was 
therefore selected as most likely to provide the accurate age-
specific estimates of the proportion of the population suffering 
from relevant chronic diseases in the EU countries. The survey was 
undertaken with government support, gave age-stratified results, 
avoided double counting and included medical validation through 
doctors’ opinions on whether a patient’s illness was significant 
enough to deserve immunisation. These age-specific proportions 
were then applied to the 2006 populations of all EU countries 
(derived from Eurostat; http://epp.eurostat.ec.europa.eu/) to provide 
country-specific estimates of those under age 65 with one or more 
conditions that would put them into the chronic disease risk group 
category. These totals were added to the Eurostat estimates of the 
number of the elderly aged 65 years and older to estimate the 
proportion of the population that was either suffering from one or 
more chronic diseases or was aged 65 years and older for each EU 
country and the EU as a whole. 
3FTVMUT
Literature providing evidence on whether persons in certain 
categories are at higher than average risk of experiencing severe 
disease when infected with influenza are summarised in Table 1 
along with relevant studies showing the effectiveness of vaccination 
in reducing this risk. The Table does not attempt to show all the 
studies but selects typical studies or describes the conclusions of 
reviews.
Older people 
The data strongly support the WHO position that older people 
are at higher risk of severe illness, hospitalisation and death if 
they are infected with influenza, compared to younger adults. The 
data also show that immunisation significantly reduced this risk 
of adverse outcomes, though the protection afforded is lower than 
for younger people. The protection was somewhat less for the more 
severe outcomes (hospitalisation, pneumonia and death) than it 
is for all influenza but it was still significant both statistically and 
from a public health perspective.   
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Ta b l e  1
Selected articles providing evidence on the risk groups for in&uenza vaccination
Target population
Risk group Study type Outcome measure provided Comments
Individuals aged 65 years and older (Group 1)
Guidelines 
[27] Not applicable
US-CDC updated recommendations for seasonal 
vaccination. Includes a comprehensive review of articles 
supporting vaccination of various risk groups. It is 
mainly based on evidence coming from the United States 
(US).
Cohort [5] VE against hospitalisation 21% (95% CI: 17%-26%). VE against death 12% (95% CI: 8%-16%).
Large cohort study conducted in the United Kingdom (UK) 
covering a 10-year period. Provides robust data on the 
effectiveness of vaccination in the elderly (≥65 years old) 
against hospitalisation and death. 
Cohort [3] 
Incidence of hospitalisation for pneumonia/
influenza or death: 8.2/1,000 for healthy and 
38.4/1,000 for high-risk individuals. VE against 
hospitalisation 48% (95% CI: 42%-52%)
Large cohort study conducted in the US. Provides rates of 
death/hospitalisation for healthy and high-risk elderly as 
well as VE data.
Time series 
analysis [28] 
Excess hospitalisations higher in persons ≥65 
years old (10 per 100,000)
Large study based on hospital discharge records from 
all public hospitals in Spain covering four influenza 
seasons. Excess hospitalisations attributable to influenza 
significantly higher in those ≥65 years old. 
Chronic illness (Group 2)
Chronic respiratory 
diseases
Review [29] 
Influenza vaccination reduced the development 
of severe respiratory complications and 
hospitalisation by 50-80%, and death from both 
respiratory disease and all causes by 40-55%.
 
RCT [8] VE against influenza-confirmed ARI 76% among individuals with COPD.
VE was not influenced by the severity of COPD. None of 
the vaccinated patients required mechanical ventilation 
because of influenza-related ARI. By contrast, all the 
unvaccinated patients with moderate-to-severe COPD 
who were hospitalised because of influenza-related ARI 
needed assisted ventilation.
Chronic cardiovascular 
disease
Cohort [8] 
Vaccination reduced the risk of cardiovascular 
death - RR 0.34 (95% CI: 0.17%-0.7%1) in 
individuals with stable coronary hearth disease.
Restrospective 
cohort [30-32] 
Higher risk of acute myocardial infarction 
shortly after an acute respiratory infection (not 
necessarily influenza) RR 4.95 (95% CI: 4.43%-5.53%) 
The study was based on the United Kingdom General 
Practice Research Database, which contains computerised 
medical records of more than five million patients.
Metabolic disorders 
(Including diabetes 
mellitus)
Case control 
[10-11] 
Influenza vaccine effectiveness in diabetics was 
79% (95% CI: 19%-95%)
 
Cohort [9]
Higher risk of hospitalisations, OR: 2.19 (95% CI: 
1.08%-4.47%), and of any complication, OR: 1.74 
(95% CI: 1.16%-2.61%), among non-elderly adults 
with diabetes.
Chronic renal and hepatic 
diseases
Case series 
analysis 
[33,34] 
Excess influenza-attributable mortality in 
patients on dialysis. 
Literature 
review
[34] 
Increased incidence of respiratory infections in 
patients with chronic kidney disease.
Immunosuppressed Review [35] Higher incidence of complication among organ and haematopoietic stem cell recipients.
HIV
Meta-analysis 
[36-38] 
Pooled relative risk reduction of 66% (95% CI: 
36%-82%).
The study of the highest quality, an RCT, yielded the most 
conservative estimate (RRR 41%; 95% CI: 2%-64%) 
Cohort [37] 
Influenza accounted for 42% of ARI among HIV-
infected individuals followed up in a single 
clinic.
Probably high incidence of disease, but no evidence of 
more severe disease than in healthy population.
Young people taking 
salicylates long-term Review [39] 
Theoretical risk of developing severe disease 
(Reye syndrome) among people under the age of 
20 taking salicylates.
A causal association was never established.
Other groups
Pregnant women
(Group 3)
Review [12] Not applicable
Evidence is contradictory on pregnancy as risk factor 
for more severe influenza disease in women who are 
otherwise healthy.
Pregnant women with risk 
factors (Group 3) Review [12] 
Occurrence of acute respiratory illness was 
more likely than among healthy pregnant women 
OR: 3.2 (95% CI: 3%-3.5%). Influenza-attributable 
rate of hospital admission was increasing with 
pregnancy trimester: 3.9 (−6.4 to 14.2), 6.7 (−4.1 
to 17.5), and 35.6 (21.1 to 50·1) respectively/per 
10,000 woman-months.
 
Children 
(Group 4)
ECDC technical 
report  [18] 
Data for young children, particularly under two 
years of age, are scant from European countries. 
Routine immunisation of school-age children has 
an indirect beneficial effect for adults and the 
elderly in terms of reduced disease burden.
This report was developed by a panel of experts who 
reviewed the available literature up to January 2007.
Abbreviations: ARI, acute respiratory tract illness; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ECDC, European Centre for Disease Prevention 
and Control; HIV, human immunodeficieancy virus; OR; odds ratio; RCT, randomised controlled trial; RR, relative risk; RRR, relative risk reduction; US-CDC, United States 
Centers for Disease Control and Prevention; VE, vaccine effectiveness;
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There is uncertainty concerning the age ‘cut-off’, the lower 
age threshold above which all people should be recommended 
the vaccine and the data are not consistent with any precise age 
although as people get older the risk rises [28,40].  The age group 
most commonly stated as being routinely offered immunisation is 
of persons aged 65 years and older [15]. There are some exceptions 
to this and a few European countries have adopted policies for 
immunising younger persons and have lower age thresholds, others 
still are at present reviewing their policies with a view to lowering 
their age-limits [15]. One analysis sponsored by industry suggested 
reducing the age cut-off to 50 years [24]. 
Children 
In 2006-7, an independent scientific panel convened by 
ECDC found there was then insufficient data to support starting 
widespread immunisation of children though the vaccines did 
induce immunity [18]. That review found considerable data from 
outside Europe but little that was from Europe itself, notably on 
the burden of disease in children. Our present review finds that 
this has not changed, although there is equally no evidence against 
immunising children. 
Ta b l e  2
Country-speci(c estimates of the population in the two major risk groups for European Union countries*, 2006
Number aged 65 years or over1 Number under 65 years-old with one or more risk morbidities2  Total “at risk”
Country No. of people % of country’s population No. of people
% of country’s 
population No. of people
% of country’s 
population
Austria 1,403,000 16.9 689,000 8.3 2,091,000 25.2
Belgium 1,810,000 17.1 879,000 8.3 2,689,000 25.4
Bulgaria 1,325,000 17.3 637,000 8.3 1,962,000 25.6
Cyprus 96,000 12.3 65,000 8.3 160,000 20.6
Czech Republic 1,482,000 14.4 853,000 8.3 2,336,000 22.7
Denmark 835,000 15.3 452,000 8.3 1,287,000 23.6
Estonia 229,000 17.1 111,000 8.3 340,000 25.4
Finland 869,000 16.5 437,000 8.3 1,306,000 24.8
France 10,277,000 16.2 5,262,000 8.3 15,539,000 24.5
Germany 16,299,000 19.8 6,832,000 8.3 23,131,000 28.1
Greece 2,074,000 18.6 927,000 8.3 3,001,000 26.9
Hungary 1,605,000 15.9 835,000 8.3 2,441,000 24.2
Ireland 478,000 11.1 358,000 8.3 836,000 19.4
Italy 11,772,000 19.9 4,907,000 8.3 16,681,000 28.2
Latvia 389,000 17.1 189,000 8.3 579,000 25.4
Lithuania 527,000 15.6 280,000 8.3 808,000 23.9
Luxemburg 67,000 14.0 40,000 8.3 106,000 22.3
Malta 56,000 13.8 34,000 8.3 91,000 22.1
Netherlands 2,368,000 14.5 1,358,000 8.3 3,726,000 22.8
Poland 5,116,000 13.4 3,164,000 8.3 8,280,000 21.7
Portugal 1,828,000 17.3 879,000 8.3 2,708,000 25.6
Romania 3,204,000 14.9 1,789,000 8.3 4,993,000 23.2
Slovakia 640,000 11.9 447,000 8.3 1,087,000 20.2
Slovenia 320,000 15.9 166,000 8.3 486,000 24.2
Spain 7,407,000 16.7 3,691,000 8.3 11,098,000 25.0
Sweden 1,581,000 17.4 756,000 8.3 2,338,000 25.7
United Kingdom 9,752,000 16.0 5.051,000 8.3 14,802,000 24.3
Total EU 27 83,813,000 16.9% 41,095,000 8.3% 124,909,000 25.2%
* Note numbers have been rounded to the nearest thousand so column totals will not necessarily add up.
1 Eurostat data, average population by sex and five-year age groups, 2006 (date of extraction: 11 Feb 2008)
2 Based on methodology of Fleming and Elliot (2006) [26]
Two other sources of information show similar estimates for specific countries: 
Belgium: Based on the Health Interview Survey (HIS) last conducted in 2004 in Belgium [46], where people at risk were elderly or those with a chronic disease, 30.2% 
of the total population were at risk and considered for immunisation in 2004 which is consistent with the estimate applying Fleming and Elliot’s findings of 25.4%. 
In absolute numbers, the population aged 65 years or older amounted to 1,789,812 individuals in 2004, and the population between 15- and 64-years-old with chronic 
health problems was estimated at 1,353,366 individuals. People with more than one chronic disease are not counted twice. Chronic conditions that were taken into 
consideration were similar to the ones counted in Fleming and Elliot (2006) [26].
France: The estimated number of people aged 65 years or older was around 9,100,000 (14.4% of the population of France) in 2007. The number of people who have used 
the social security system (because of chronic illness) was estimated at 7,700,000 (13.6%) in 2006 (L’assurance maladie, Caise national 2007 [47]). This means that the 
proportion of people in risk groups was about 28.0% of the total population which is close to the ECDC estimate of 24.5% applying Fleming and Elliot’s data.  
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Persons with chronic medical conditions  
Our review also supports the position that people of all ages with 
certain broad categories (as listed in Table 1) of chronic medical 
conditions are at higher risk for severe disease. However, there are 
much fewer published data that demonstrate that vaccination can 
reduce the risk of adverse outcomes in this group than there are for 
the older age-groups. When it comes to specific conditions (rather 
than broad groups), there is usually insufficient epidemiological 
scientific information to support immunisation, unless the condition 
is relatively common such as diabetes. 
Our review of the literature also found that patients with more 
common milder conditions such as mild hypertension, mild asthma, 
asymptomatic HIV infection or controlled HIV disease with normal 
immune function have not been investigated for either an increased 
risk from influenza infection or the impact of vaccination.   
Healthy pregnant women 
Healthy pregnant women are another group where the case 
has been made for offering immunisation. It is policy in eight EU 
countries to offer the vaccine to healthy pregnant women [12,15], 
based on more complex arguments than in the case of children, 
reflecting both whether there is evidence of increased risk of severe 
disease in the women and whether or not this is a mechanism 
for providing direct and indirect protection of newborn babies by 
protecting their pregnant and nursing mothers [27]. There is only 
limited evidence from Europe of increased risk for severe disease 
in healthy pregnant women and hardly any evidence as yet of 
impact of immunisation, though the vaccines do induce immunity 
[12]. What evidence exists is conflicting and much of it is from 
outside Europe [12]. There are no data against immunising healthy 
pregnant women, but equally few data from Europe on the burden 
of influenza in pregnant women and none on the effectiveness of 
vaccination in reducing that burden. One recent blinded randomised 
trial of immunisation of pregnant women showed benefit for both 
mother and child in terms of reduced acute respiratory infection. 
But that study was conducted in a tropical country [41]. 
Other groups to whom vaccination is recommended 
Many countries recommend immunising healthcare workers 
and there are occupational health reasons for doing so in order 
to protect the health of staff themselves [15], but that issue is 
outside the scope of this paper [42,43]. However immunisation 
of staff to protect people in risk groups is important to recognise. 
Randomised community trials (one conclusive community trial 
and another giving supportive evidence) of immunising care home 
staff have convincingly demonstrated that this reduces mortality 
in the elderly and chronically ill patients and therefore can be 
recommended [44,45]. In terms of protecting risk groups, we could 
identify no conclusive data that would support or refute policies for 
immunising other groups of staff or family carers.
Proportion of the population targeted by immunisation 
Broad estimates of the number of people and the proportion of 
the population falling under the two main risk groups for influenza 
in EU countries and in the EU as a whole are shown in Table 2. The 
national range is from 19% to 28% depending on the proportion 
of the elderly in the population in each country. The EU total is 
estimated to be around 125 million people, with around 84 million 
persons aged 65 years or older and around 41 million younger 
persons living with chronic illness. 
%JTDVTTJPO
Although there are a number of published studies on burden of 
disease and vaccination effectiveness in risk groups, relatively few 
of these are based on data from European countries. Therefore, 
evidence was considered also from other countries, especially 
on the effectiveness of vaccination in protecting risk groups. A 
particular gap is the lack of data on burden of severe disease 
due to influenza in Europe and surveillance for so called severe 
acute respiratory infection (SARI) in particular in children and 
pregnant women. It is notable that while there is good laboratory 
surveillance and surveillance of those presenting to primary care 
services with influenza in Europe (so far undertaken through the 
European Influenza Surveillance System (EISS; http://www.eiss.
org/) and WHO National Influenza Centres (http://www.who.int/
csr/disease/influenza/centres/en/index.html) working with WHO 
Global Influenza Surveillance Network (GISN; http://www.who.int/
csr/disease/influenza/influenzanetwork/en/index.html) there are no 
routine European systems of surveillance for persons with severe 
adverse outcomes due to influenza. Similarly, there is no routine 
evaluation of influenza vaccine effectiveness in Europe. Therefore, 
the task of objectively determining the burden of influenza disease, 
which groups are at risk of severe disease from influenza in Europe 
and of these which would gain most from immunisation is not 
as straightforward an exercise as it could be. This is especially 
pertinent as the characteristics of influenza can change annually 
leading to significant short term and perhaps longer term variations 
in the severity of disease and the vaccine effectiveness [6]. 
Estimates of the impact of influenza vaccines on morbidity and 
mortality are variable [4,5,48,49]. This is inevitable when citing 
studies with non-specific outcomes (e.g. all cause or respiratory-
related deaths) which always dilute the effects generally found 
in studies with laboratory-confirmed outcomes. Even in the latter 
studies it is important to allow for the role of confounding factors. 
Both positive confounding due for example to the “healthy vaccinee 
effect”, as well as negative confounding associated with serious pre-
existing medical conditions being more frequent among vaccinees 
(counfounding by indication) can bias vaccine effectiveness up- and 
downwards respectively. The diluting effect and the predominance 
of negative confounding in a particular study population explains 
why some reviews of effect from the influenza vaccine may conclude 
by showing no protection [48].
That said, the evidence supporting the WHA policy for selectively 
immunising the two risk groups: older people and those with chronic 
ill-health in Europe is sufficiently strong. Though immunising older 
people is not a panacea in protecting them against influenza, on 
balance, it certainly reduces their risk of infection and the more 
severe outcomes. There is no consensus on what exactly is the 
age cut-off for ‘older people’ in Europe and there has been no 
EU level debate on this subject. Defining a cut-off is beyond the 
scope of this paper. It also needs to be borne in mind that the age-
structure varies across EU countries as do the costs of healthcare 
and income levels and with these the relative costs and benefits of 
influenza disease and immunisation respectively. Hence it could 
be quite reasonable for national age cut-offs to differ. However 
what data and analyses there are suggest the age of 65 years and 
over as the current threshhold and this is at least a reasonable 
minimum recommendation for policy decisions. Concerning the 
youngest age groups the lack of data from Europe makes decisions 
over childhood vaccination difficult. It should be noted that three 
counties, Finland and neighbouring Estonia and Latvia have 
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recently started immunising children routinely and it is expected 
that this will provide information on both the burden and impact 
of immunisation [15]. 
There are difficulties in defining the chronic conditions. Some 
national authorities take the approach of coming up with lists 
of medical and physical conditions for which immunisation is 
recommended. Others have taken the more pragmatic approach of 
defining broad categories, e.g. “all chronic metabolic conditions” 
[50,51]. In our view, the latter broad brush approach is preferable 
for two reasons. When it comes to individual rare conditions the 
numbers are always too low to research and so there can only 
be presumed evidence of increased risk, and even less of the 
effectiveness of vaccination in reducing that risk. Also there 
are always uncommon conditions that may have been omitted 
from the lists. Finally comparison between various EU countries 
show differences between the detailed national lists while the 
broad-brush lists all look the same along the lines of Table 1. A 
problem with both approaches is whether to include mild conditions 
that are technically chronic diseases but for which there is in 
fact no demonstrated evidence of increased risk of benefit from 
immunisation. 
When it comes to estimating the number of persons at risk, 
more credibility should be afforded to the data in our review for the 
elderly population than that for the people under age of 65 years 
with chronic illnesses, since the latter data rely on application of 
results obtained from one country’s survey to all other countries. 
However, the results for chronic illness are similar to what is found 
in an independent study undertaken by Ryan et al. though the 
overall estimates are greater in Ryan et al. because they include 
people down to the age of 50 years [24] and prevalence surveys in 
Belgium [46] and France [47] came up with results that were within 
a few percentage points of what we derived for those countries 
applying Flemings estimates (Table 2). Both the two independent 
country estimates were somewhat higher than our estimate but that 
may reflect that their surveys were without medical verification. 
Our calculations suggest that EU countries would currently 
need to immunise about one quarter of their population annually 
covering the two major risk groups. Projections of expected 
demographic trends to 2050 indicate that the absolute numbers 
and proportions of the older age groups will rise inexorably over 
time in Europe because of aging populations; from the range of 
11-19% in 2004 to 22-35% in 2050 [20,52] (Figure 1). It is 
less clear what will happen with the size of younger populations 
with chronic illness. Common sense suggests that the success of 
modern medicine in permitting people with chronic illness like HIV 
infection to live productive lives will also result in the increase of 
the proportion of the population with chronic illnesses. Also some 
secular changes like increasing obesity and declining levels of 
exercise may independently increase the prevalence of conditions 
like maturity onset diabetes and cardiovascular disease. Some 
limited confirmation of this hypothesis comes from the surveys 
undertaken by the University of Zurich which show a slow increase 
in prevalence of people with self-reported ill-health in telephone 
surveys [53].
Despite the limited scientific basis for recommending influenza 
vaccination to healthcare workers in general there is no evidence 
against it either. Therefore the decisions taken by some countries 
to recommend immunisation to such groups are reasonable, even if 
they cannot yet be scientifically supported and conclusively shown 
to protect patients [54].
In conclusion, existing evidence indicate that the elderly and 
people with chronic diseases are at higher risk of severe adverse 
outcome of influenza and that immunisation reduces this risk. Our 
work has also highlighted a number of gaps in the evidence thus 
suggesting a number of obvious priorities for studies that could 
be performed in individual countries or at EU level. Specifically 
these are: 
• Surveillance development – routine surveillance for severe 
manifestations of influenza and other respiratory infections in 
Europe (hospitalisations and death). This can be referred to as 
severe acute respiratory infection (SARI).
• Routine monitoring of the effectiveness of influenza vaccination 
against different outcomes. Such monitoring is currently piloted 
by ECDC, Epiconcept and EU Member States [55]. 
• Estimation of the burden of disease from influenza in pregnant 
women and children and evaluation of the impact of immunising 
these groups. 
• Development of projects for stronger promotion of influenza 
immunisation among healthcare workers both for their own 
benefit and for that of their patients coupled with studies to 
investigate whether or not immunisation of healthcare staff and 
household members reduces risk in vulnerable people in the 
two main risk groups.
F i g u r e  1
Percentage of population aged 65 years and older: 2004 census data 
compared with 2050 projected data
Data not stated for: Bulgaria, Romania (joined EU in 2007), Iceland and Norway
Data as published for Luxembourg and Malta
Source: The Economic Policy Committee (EPC) and European Commission (EC), 
December 2005 [20]
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• Specific investigation as to whether or not there are higher levels 
of risk of severe disease from influenza infection in HIV-infected 
persons in Europe and similar studies for other more common 
conditions such as mild asthma.
• Development of cross-European health impact and health 
economic frameworks for policy-informing studies on influenza 
immunisation, for example regarding the cut-off ages of 
immunisation in the elderly recognising that there may be 
reasons for variation between countries.
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